Aprea Therapeutics, Inc.
APRE
We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$14M
▲ +2.8% YoY
Op. Margin
–
ROIC
-38.13%
▼ -3.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$13M
▲ +5.0% YoY
Op. Cash Flow (TTM)
-$13M
▲ +4.9% YoY
Net Debt
-$38M
Net Cash Position
Cash & Equiv.
$38M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with APRE
Aprea Therapeutics (APRE) in two numbers
Questions about Aprea Therapeutics
Does Aprea Therapeutics (APRE) pay a dividend?
No. Aprea Therapeutics (APRE) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 4 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in APRE's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing APRE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.